Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Brentuximab Vedotin MeSH Descriptor Data 2025


MeSH Heading
Brentuximab Vedotin
Tree Number(s)
D12.644.456.217
D12.776.124.486.485.114.224.060.438
D12.776.124.790.651.114.224.060.469
D12.776.377.715.548.114.224.200.469
Unique ID
D000079963
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000079963
Scope Note
Immunoconjugate that consists of the chimeric monoclonal anti - CD30 ANTIGEN antibody cAC-10 conjugated to monomethyl auristatin E. It is used for the treatment of LYMPHOMA.
Entry Term(s)
Adcetris
CAC10-1006
SGN-35
cAC10-vcMMAE
Pharm Action
Immunotoxins
Antineoplastic Agents, Immunological
Registry Numbers
7XL5ISS668
0
Related Numbers
914088-09-8
Public MeSH Note
2020; BRENTUXIMAB VEDOTIN was indexed under IMMUNOCONJUGATES 2010-2019
History Note
2020 (2010)
Date Established
2020/01/01
Date of Entry
2019/07/08
Revision Date
2019/01/15
Brentuximab Vedotin Preferred
SGN-35 Narrower
Adcetris Narrower
CAC10-1006 Narrower
cAC10-vcMMAE Narrower
page delivered in 0.162s